595 related articles for article (PubMed ID: 24304686)
1. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK.
Schmuhl E; Ramer R; Salamon A; Peters K; Hinz B
Biochem Pharmacol; 2014 Feb; 87(3):489-501. PubMed ID: 24304686
[TBL] [Abstract][Full Text] [Related]
2. Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol.
Qiao Z; Kumar A; Kumar P; Song ZH
Exp Eye Res; 2012 Jul; 100():59-64. PubMed ID: 22580290
[TBL] [Abstract][Full Text] [Related]
3. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Mo FM; Offertáler L; Kunos G
Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
[TBL] [Abstract][Full Text] [Related]
4. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling.
Su JY; Vo AC
Eur J Pharmacol; 2007 Mar; 559(2-3):189-95. PubMed ID: 17292352
[TBL] [Abstract][Full Text] [Related]
5. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
6. Decisive role of P42/44 mitogen-activated protein kinase in Δ
Lüder E; Ramer R; Peters K; Hinz B
Oncotarget; 2017 Dec; 8(62):105984-105994. PubMed ID: 29285308
[TBL] [Abstract][Full Text] [Related]
7. Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells.
Robinson AJ; Dickenson JM
Eur J Pharmacol; 2001 Feb; 413(2-3):151-61. PubMed ID: 11226388
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Cui YY; D'Agostino B; Risse PA; Marrocco G; Naline E; Zhang Y; Chen HZ; Finance O; Rinaldi-Carmona M; Rossi F; Advenier C
Eur J Pharmacol; 2007 Nov; 573(1-3):206-13. PubMed ID: 17643417
[TBL] [Abstract][Full Text] [Related]
9. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
Dhopeshwarkar A; Mackie K
J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477
[TBL] [Abstract][Full Text] [Related]
10. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.
Curto-Reyes V; Boto T; Hidalgo A; Menéndez L; Baamonde A
Eur J Pharmacol; 2011 Oct; 668(1-2):184-9. PubMed ID: 21771590
[TBL] [Abstract][Full Text] [Related]
12. Neuronal nitric oxide synthase-dependent elevation in adiponectin in the rostral ventrolateral medulla underlies g protein-coupled receptor 18-mediated hypotension in conscious rats.
Penumarti A; Abdel-Rahman AA
J Pharmacol Exp Ther; 2014 Oct; 351(1):44-53. PubMed ID: 25100751
[TBL] [Abstract][Full Text] [Related]
13. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.
Offertáler L; Mo FM; Bátkai S; Liu J; Begg M; Razdan RK; Martin BR; Bukoski RD; Kunos G
Mol Pharmacol; 2003 Mar; 63(3):699-705. PubMed ID: 12606780
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
15. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors.
Franklin A; Stella N
Eur J Pharmacol; 2003 Aug; 474(2-3):195-8. PubMed ID: 12921861
[TBL] [Abstract][Full Text] [Related]
16. Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery.
Ho WS; Hiley CR
Br J Pharmacol; 2003 Apr; 138(7):1320-32. PubMed ID: 12711633
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
Ramer R; Hinz B
J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
[TBL] [Abstract][Full Text] [Related]
18. Abnormal cannabidiol confers cardioprotection in diabetic rats independent of glycemic control.
Matouk AI; Taye A; El-Moselhy MA; Heeba GH; Abdel-Rahman AA
Eur J Pharmacol; 2018 Feb; 820():256-264. PubMed ID: 29274332
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.
Martín-Moreno AM; Reigada D; Ramírez BG; Mechoulam R; Innamorato N; Cuadrado A; de Ceballos ML
Mol Pharmacol; 2011 Jun; 79(6):964-73. PubMed ID: 21350020
[TBL] [Abstract][Full Text] [Related]
20. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction.
Sánchez MG; Ruiz-Llorente L; Sánchez AM; Díaz-Laviada I
Cell Signal; 2003 Sep; 15(9):851-9. PubMed ID: 12834810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
